Pfizer Inc. (PFE)
NYSE: PFE · Real-Time Price · USD
25.11
-0.13 (-0.53%)
Oct 10, 2025, 10:15 AM EDT - Market open
Pfizer Revenue
Pfizer had revenue of $14.65B in the quarter ending June 29, 2025, with 10.31% growth. This brings the company's revenue in the last twelve months to $63.83B, up 13.54% year-over-year. In the year 2024, Pfizer had annual revenue of $63.63B with 6.84% growth.
Revenue (ttm)
$63.83B
Revenue Growth
+13.54%
P/S Ratio
2.24
Revenue / Employee
$788,062
Employees
81,000
Market Cap
142.74B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 63.63B | 4.07B | 6.84% |
Dec 31, 2023 | 59.55B | -41.62B | -41.14% |
Dec 31, 2022 | 101.18B | 19.89B | 24.46% |
Dec 31, 2021 | 81.29B | 39.64B | 95.16% |
Dec 31, 2020 | 41.65B | 746.00M | 1.82% |
Dec 31, 2019 | 40.91B | 80.00M | 0.20% |
Dec 31, 2018 | 40.83B | -11.72B | -22.31% |
Dec 31, 2017 | 52.55B | -278.00M | -0.53% |
Dec 31, 2016 | 52.82B | 3.97B | 8.13% |
Dec 31, 2015 | 48.85B | -754.00M | -1.52% |
Dec 31, 2014 | 49.61B | -1.98B | -3.84% |
Dec 31, 2013 | 51.58B | -3.07B | -5.62% |
Dec 31, 2012 | 54.66B | -6.38B | -10.45% |
Dec 31, 2011 | 61.04B | -4.13B | -6.34% |
Dec 31, 2010 | 65.17B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PFE News
- 1 hour ago - Pfizer's Q3: The Catalyst For A Bullish Resurgence (Earnings Preview) - Seeking Alpha
- 17 hours ago - Pfizer Declares Fourth-Quarter 2025 Dividend - Business Wire
- 2 days ago - Mikael Dolsten, M.D., Ph.D., Joins TRIO Pharmaceuticals as Chairman - Business Wire
- 3 days ago - Pfizer Offers High Yield And Capital Appreciation Opportunities (Technical Analysis) - Seeking Alpha
- 3 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 4 days ago - Pfizer: TrumpRx Unlocks Opportunities With Drug Discounts - Seeking Alpha
- 6 days ago - 5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (Oct. 2025) - Seeking Alpha
- 6 days ago - The Score: Pfizer, Tesla, Electronic Arts and More Stocks That Defined the Week - WSJ